Virginia Cancer Specialists, PC
Gainesville, Virginia 20155
1 studies enrolling now · 12 studies all time
What they study most
Biliary Tract Neoplasms, Breast Cancer, Cancer, Carcinoma, Non-Small-Cell Lung, Chronic Lymphocytic Leukemia, HER2 Mutations Breast Neoplasms, HER2 Positive Breast Cancer, HER2-positive Breast Cancer, Kahler Disease, Kidney Neoplasms, Low Grade Ovarian Serous Adenocarcinoma, Low Grade Serous Ovarian Cancer
Studies at this site
- A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer — Recruiting now
- A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer — Running, not enrolling
- Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) — Running, not enrolling
- A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer — Completed
- Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma — Completed
- Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations — Running, not enrolling
- A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation — Running, not enrolling
- Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma — Running, not enrolling
- The Circulating Cell-free Genome Atlas Study — Status unconfirmed
- Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC) — Completed
- Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer — Completed
- Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer — Completed